Top left Img Top left Img
top left sm
company dotsp people dotsp science dotsp products dotsp clinical dotsp news/events dotsp contact us dotsp glossary dotsp home


Investor Contact
Jeffrey Hwang
(212) 582-1199
jhwang@irxtherapeutics.com

R. Breck Denny
(212) 582-1199
rbdenny@irxtherapeutics.com

Paula Ehrenberg
(212) 582-1199
pehrenberg@irxtherapeutics.com

IRX Fact Sheet
For more information, download the IRX Fact Sheet:
Download the IRX Fact Sheet
Company Profile/Fact Sheet
Download our Fact Sheet by clicking on the icon to the right.

News/Press Releases

DATE TITLE (CLICK TO DOWNLOAD PDF)
July 22, 2008 acrobat logo IRX Therapeutics Announces Results of Phase 2 Study for IRX-2
July 15, 2008 acrobat logo IRX Therapeutics to Present Phase 2 Results at 7th International Conference on Head and Neck Cancer
June 16, 2008 acrobat logo IRX Therapeutics Names Scott M. Freeman, M.D. Chief Operating Officer
June 3, 2008 acrobat logo IRX Therapeutics Completes $25 Million Series A Preferred Stock Offering
May 2, 2008 acrobat logo IRX Therapeutics to Present Phase 2b Results at 3rd European Conference on Head & Neck Oncology
January 25, 2008 acrobat logo Carol R. Epstein, M.D. Joins IRX Therapeutics As Chief Medical Officer
January 3, 2008 acrobat logo IRX Therapeutics to Present at the 26th Annual JP Morgan Healthcare Conference
October 4, 2007 acrobat logo Declan P. Doogan, M.D. joins IRX therapeutics as Advisor on Global Product Development
May 24, 2007 acrobat logo IRX Therapeutics Completes Second $12.5 Million Convertible Note Offering
March 16, 2007 acrobat logo IRX Therapeutics Presents at the 27th Annual Cowen and Company Health Care Conference
January 16, 2007 acrobat logo IRX Therapeutics Names John W. Hadden II President and CEO
January 5, 2007 acrobat logo IRX Therapeutics to Present at the 25th Annual JP Morgan Healthcare Conference
November 28, 2006 acrobat logo IRX Therapeutics Announces that Jean Louis Lefebvre, M.D. Has Joined its Medical Advisory Board
March 29, 2006 acrobat logo IRX Therapeutics Raises $12.5 Million; Adds Frank J. Loverro to its Board of Directors
October 17, 2005 acrobat logo IRX Therapeutics Enrolls First Patients in IRX-2 Phase II Head and Neck Cancer Study
May 5, 2005 acrobat logo IRX Therapeutics Announces the Election of John T. Spitznagel As Chairman of its Board of Directors
© 2008 IRX Therapeutics site design: dkbmarketing